FILTER
FILTERED INTERVIEW RESULTS
Martin Sack
REGIONAL HEAD AMERICAS, LESCHACO
Leschaco is a freight forwarder expanding its’ services and network across the Americas.
James Sapirstein
PRESIDENT AND CEO, AZURRX BIOPHARMA
AzurRx BioPharma is a development stage biopharmaceutical company focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions.
Dr. Trevor P. Castor
PRESIDENT & CEO, APHIOS
Aphios’ vision is to develop biotechnology products for improving health and treating chronic diseases in an environmentally sustainable manner.
Jay Shukla
PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS
Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and OTC products for the North American market.
Doug Giordano
SENIOR VP OF BUSINESS DEVELOPMENT, PFIZER
Pfizer outlines its plans to build its pipeline through partnerships as the company increasingly focuses on new science.
Michael Gladstone
PRINCIPAL, ATLAS VENTURE
Atlas Venture is an early-stage venture capital firm that invests in life sciences startup companies in the US.
David DeJean
SENIOR VICE PRESIDENT, SYSTECH INTERNATIONAL
Systech International is a technology leader in supply chain safety and brand protection.
Robert Foster
CEO, HEPION PHARMACEUTICALS
Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease.
Daniel J O’Connor
PRESIDENT & CEO, ONCOSEC MEDICAL INCORPORATED
OncoSec is a late-stage biotechnology company developing immunotherapy cancer treatments using its plasmid DNA delivery platform.
Peter Meath
MANAGING DIRECTOR & CO-HEAD OF HEALTHCARE AND LIFE SCIENCES, J.P. MORGAN COMMERCIAL BANKING
.P.Morgan explains the complete ecosystem that it has developed for life science companies, aiming to serve their needs throughout their entire life cycle, from opening a bank account on Day 1, to expanding internationally and through a potential IPO and beyond.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2024 - Digital Interactive
"Cautious optimism. These two words best describe the state of mind of life sciences executives as we enter the second half of 2024. "
"Cautious optimism. These two words best describe the state of mind of life sciences executives as we enter the second half of 2024. "
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
